[2-((2,4-dihydroxyphenyl)sulfonyl)isoindoline-4,6-diol]

ID: ALA4082531

Chembl Id: CHEMBL4082531

Cas Number: 1564265-82-2

PubChem CID: 72376512

Max Phase: Preclinical

Molecular Formula: C14H13NO6S

Molecular Weight: 323.33

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  O=S(=O)(c1ccc(O)cc1O)N1Cc2cc(O)cc(O)c2C1

Standard InChI:  InChI=1S/C14H13NO6S/c16-9-1-2-14(13(19)4-9)22(20,21)15-6-8-3-10(17)5-12(18)11(8)7-15/h1-5,16-19H,6-7H2

Standard InChI Key:  SVUZJWAAXPEMKJ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA4082531

   2-[(2,4-Dihydroxyphenyl)sulfonyl]-2,3-Dihydro-1h-Isoindole-4,6-Diol

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 323.33

Molecular Weight (Monoisotopic): 323.0464

AlogP: 1.21

#Rotatable Bonds: 2

Polar Surface Area: 118.30

Molecular Species: NEUTRAL

HBA: 6

HBD: 4

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 7.08

CX Basic pKa: ┄

CX LogP: 1.29

CX LogD: 0.79

Aromatic Rings: 2

Heavy Atoms: 22

QED Weighted: 0.66

Np Likeness Score: -0.06

References

1. Tso SC, Lou M, Wu CY, Gui WJ, Chuang JL, Morlock LK, Williams NS, Wynn RM, Qi X, Chuang DT..  (2017)  Development of Dihydroxyphenyl Sulfonylisoindoline Derivatives as Liver-Targeting Pyruvate Dehydrogenase Kinase Inhibitors.,  60  (3): [PMID:28085286] [10.1021/acs.jmedchem.6b01540]

2. Brough PA, Baker L, Bedford S, Brown K, Chavda S, Chell V, D'Alessandro J, Davies NG, Davis B, Le Strat L, Macias AT, Maddox D, Mahon PC, Massey AJ, Matassova N, McKenna S, Meissner JW, Moore JD, Murray JB, Northfield CJ, Parry C, Parsons R, Roughley SD, Shaw T, Simmonite H, Stokes S, Surgenor A, Stefaniak E, Robertson A, Wang Y, Webb P, Whitehead N, Wood M..  (2017)  Application of Off-Rate Screening in the Identification of Novel Pan-Isoform Inhibitors of Pyruvate Dehydrogenase Kinase.,  60  (6): [PMID:28199108] [10.1021/acs.jmedchem.6b01478]

3. Lee D, Pagire HS, Pagire SH, Bae EJ, Dighe M, Kim M, Lee KM, Jang YK, Jaladi AK, Jung KY, Yoo EK, Gim HE, Lee S, Choi WI, Chi YI, Song JS, Bae MA, Jeon YH, Lee GH, Liu KH, Lee T, Park S, Jeon JH, Lee IK, Ahn JH..  (2019)  Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases.,  62  (2): [PMID:30623649] [10.1021/acs.jmedchem.8b01168]

4. Cao W, Wang Z, Han X, Liu J, Wang W..  (2019)  In vitro cytotoxicity screening to identify novel anti-osteosarcoma therapeutics targeting pyruvate dehydrogenase kinase 2.,  29  (20): [PMID:31495556] [10.1016/j.bmcl.2019.126665]

Source

Source(1):

• Scientific Literature